MA45148A - Composés de carfilzomib pégylés - Google Patents

Composés de carfilzomib pégylés

Info

Publication number
MA45148A
MA45148A MA045148A MA45148A MA45148A MA 45148 A MA45148 A MA 45148A MA 045148 A MA045148 A MA 045148A MA 45148 A MA45148 A MA 45148A MA 45148 A MA45148 A MA 45148A
Authority
MA
Morocco
Prior art keywords
carfilzomib compounds
pegylated carfilzomib
pegylated
compounds
carfilzomib
Prior art date
Application number
MA045148A
Other languages
English (en)
Inventor
Shabbir T Anik
Irina DOTSENKO
Gary Luehr
Ge Peng
Pasit Phiasivongsa
Dante ROMANINI
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59062074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA45148(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA45148A publication Critical patent/MA45148A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2230/00—Compositions for preparing biodegradable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Detergent Compositions (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
MA045148A 2016-05-24 2017-05-23 Composés de carfilzomib pégylés MA45148A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662340926P 2016-05-24 2016-05-24
US201762485812P 2017-04-14 2017-04-14

Publications (1)

Publication Number Publication Date
MA45148A true MA45148A (fr) 2019-04-10

Family

ID=59062074

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045148A MA45148A (fr) 2016-05-24 2017-05-23 Composés de carfilzomib pégylés

Country Status (24)

Country Link
US (3) US10517954B2 (fr)
EP (1) EP3464277B1 (fr)
JP (1) JP7142578B2 (fr)
KR (1) KR102492135B1 (fr)
CN (1) CN109415353B (fr)
AU (1) AU2017272101B2 (fr)
CA (1) CA3025170A1 (fr)
CL (1) CL2018003352A1 (fr)
CO (1) CO2018013112A2 (fr)
CR (1) CR20180602A (fr)
ES (1) ES2939849T3 (fr)
IL (1) IL263147B (fr)
MA (1) MA45148A (fr)
MX (1) MX2018014498A (fr)
NZ (1) NZ748615A (fr)
PE (1) PE20190328A1 (fr)
PH (1) PH12018502473A1 (fr)
SG (2) SG10201912278TA (fr)
TN (1) TN2018000393A1 (fr)
TW (1) TWI759301B (fr)
UA (1) UA125254C2 (fr)
UY (1) UY37253A (fr)
WO (1) WO2017205392A1 (fr)
ZA (1) ZA201807890B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
MX2020004936A (es) * 2017-11-16 2020-08-27 Amgen Inc Composiciones estables de compuestos de carfilzomib pegilado.
US20220370628A9 (en) * 2018-04-13 2022-11-24 Massachusetts Institute Of Technology Brush prodrugs and uses thereof
WO2020254602A1 (fr) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugués d'azote donneur d'électrons ou de composés comprenant une amine tertiaire
WO2021222783A1 (fr) * 2020-05-01 2021-11-04 Angiex, Inc. Conjugués anticorps anti-tm4sf-médicament et leurs procédés d'utilisation
CN113979895B (zh) * 2020-07-08 2023-03-24 中国科学技术大学 一种精确序列可控的自降解聚合物及其制备方法和应用
CN115873231A (zh) * 2022-12-17 2023-03-31 华南理工大学 一种聚乙二醇修饰的氨基糖苷类分子及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0575545B1 (fr) * 1991-03-15 2003-05-21 Amgen Inc. Pegylation de polypeptides
US20040100225A1 (en) 2002-11-20 2004-05-27 Neil Robert Miles Cooling and control system for battery charging
WO2005063777A1 (fr) 2003-12-23 2005-07-14 Corus Pharma Promedicaments de benzylphosphate et de benzylphosphate substitue utilises dans le traitement d'une inflammation pulmonaire
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US20050256324A1 (en) 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
JP4990155B2 (ja) 2004-12-07 2012-08-01 プロテオリックス， インコーポレイテッド プロテアソームを阻害するための組成物
JP5073315B2 (ja) 2006-03-24 2012-11-14 関西ペイント株式会社 缶用塗料組成物
CL2008002966A1 (es) 2007-10-04 2010-06-25 Onyx Therapeutics Inc Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros.
WO2009152160A1 (fr) 2008-06-10 2009-12-17 Gilead Sciences, Inc. Promédicaments inhalés à base de carbaprostacyclines et de prostacyclines destinés au traitement de l'hypertension artérielle pulmonaire
WO2010033240A2 (fr) 2008-09-19 2010-03-25 Nektar Therapeutics Polymères à base de glucide pour administration de médicaments et leurs conjugués
EA035100B1 (ru) 2008-10-21 2020-04-28 Оникс Терапьютикс, Инк. Комбинированная терапия с применением пептид эпоксикетонов
ES2647361T3 (es) 2010-01-07 2017-12-21 Alkermes Pharma Ireland Limited Profármacos de sales de amonio cuaternario
WO2013169282A1 (fr) 2012-05-08 2013-11-14 Onyx Therapeutics, Inc. Procédés de complexation de cyclodextrine pour la formulation d'inhibiteurs peptidiques du protéasome
UY34897A (es) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
CA2879139C (fr) 2012-07-18 2021-05-11 Onyx Therapeutics, Inc. Compositions liposomales d'inhibiteurs du proteasome a base d'epoxycetone
DE102013104003B3 (de) 2013-04-19 2014-03-13 Glatt Systemtechnik Gmbh Vorrichtung zum Einbringen einer definierten Menge eines zweiten Pulvers in einen Prozessbehälter
WO2016004221A1 (fr) 2014-07-01 2016-01-07 Mayo Foundation For Medical Education And Research Procédés et matériaux d'identification et de traitement de mammifères résistants aux traitements par inhibiteur de protéasome
CN104530413B (zh) * 2014-10-01 2017-08-25 厦门赛诺邦格生物科技股份有限公司 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
CN106310289B (zh) 2015-06-24 2020-10-13 天津键凯科技有限公司 一种聚乙二醇和麻醉药的结合物及其制备方法
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
MX2018014455A (es) 2016-05-24 2019-01-24 Basf Se Uracilpiridinas herbicidas.
BR112018072034A2 (pt) 2016-05-24 2019-02-12 Novo Nordisk A/S compostos mic-1 e usos dos mesmos
MX2018014443A (es) 2016-05-25 2019-04-15 Bayer Pharma AG 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas.
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
JP6631420B2 (ja) 2016-06-28 2020-01-15 株式会社デンソー 光センサ
WO2018003319A1 (fr) 2016-06-30 2018-01-04 パナソニックＩｐマネジメント株式会社 Procédé de fonctionnement d'un dispositif de lavage du linge, et programme associé
JP6512183B2 (ja) 2016-06-30 2019-05-15 株式会社Ｓｏｋｅｎ 乗員検知システム及び乗員検知装置
JP6851640B2 (ja) 2016-06-30 2021-03-31 Ｆｓテクニカル株式会社 供試体、アンカー試験装置およびアンカー試験方法

Also Published As

Publication number Publication date
JP7142578B2 (ja) 2022-09-27
CN109415353A (zh) 2019-03-01
UA125254C2 (uk) 2022-02-09
MX2018014498A (es) 2019-04-01
BR112018074078A2 (pt) 2019-06-04
KR20190010648A (ko) 2019-01-30
AU2017272101A1 (en) 2018-12-13
CA3025170A1 (fr) 2017-11-30
TWI759301B (zh) 2022-04-01
TN2018000393A1 (en) 2020-06-15
WO2017205392A1 (fr) 2017-11-30
CN109415353B (zh) 2023-01-10
UY37253A (es) 2017-11-30
EP3464277B1 (fr) 2022-12-28
US10675353B2 (en) 2020-06-09
PH12018502473A1 (en) 2019-04-08
US20200069808A1 (en) 2020-03-05
ES2939849T3 (es) 2023-04-27
CO2018013112A2 (es) 2018-12-28
CL2018003352A1 (es) 2019-02-15
EP3464277A1 (fr) 2019-04-10
US10517954B2 (en) 2019-12-31
ZA201807890B (en) 2019-08-28
SG11201810396QA (en) 2018-12-28
CR20180602A (es) 2019-03-04
IL263147A (en) 2018-12-31
KR102492135B1 (ko) 2023-01-26
US20200376131A1 (en) 2020-12-03
US20170340746A1 (en) 2017-11-30
US11077198B2 (en) 2021-08-03
TW201808345A (zh) 2018-03-16
NZ748615A (en) 2022-11-25
SG10201912278TA (en) 2020-02-27
JP2019519530A (ja) 2019-07-11
IL263147B (en) 2022-04-01
AU2017272101B2 (en) 2021-10-07
PE20190328A1 (es) 2019-03-05

Similar Documents

Publication Publication Date Title
MA47131A (fr) Composés benzyl-amide phosphodiamide antiviraux
MA49701A (fr) Composés immunomodulateurs
MA44233A (fr) Nouveaux composés
MA44050A (fr) Nouveaux composés
DK3519420T3 (da) Cykliske dinukleotidforbindelser
MA42293A (fr) Composés antibactériens
MA45051A (fr) Polynucléotides codant la relaxine
MA41614A (fr) Composés antiviraux
DK3361870T3 (da) Fungicidsammensætninger
FR3034146B1 (fr) Mousqueton
FR3049869B1 (fr) Harnais
MA45148A (fr) Composés de carfilzomib pégylés
DK3558995T3 (da) Polymorfer
DK3612519T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
DK3558961T3 (da) Polymorfer
MA45221A (fr) Nouveaux composés antibactériens
BR112017017193A2 (pt) compostos herbicidas
MA49522A (fr) Nouveaux composés de quinoléinone
MA43275A (fr) Composé de pyranodipyridine
DK3597189T3 (da) Krystallinske forbindelser
DK3347403T3 (da) Polyalkoxyfedtforbindelse
MA51221A (fr) Composés de pyrazolopyridinone
DK3672941T3 (da) Pyridylpyridonforbindelser
MA43799A (fr) Composés de 2-oxindole
DK3337322T3 (da) Fungicidsammensætninger